The Hedge Book logo The Hedge Book Read smarter. Invest better.

AI Stock Monitor

DIVISLAB.NS - Divi's Laboratories

Company-specific Hedge Book research coverage for Divi's Laboratories, classified in Pharmaceutical Ingredients and Contract Manufacturing within Healthcare. Verified developments are interpreted through its sector, industry, and company-specific monitoring framework.

Public company · India · Healthcare · Pharmaceutical Ingredients and Contract Manufacturing

NSE · Healthcare · Research updated · Market data updated Research and source refreshes run four times daily. The timestamps above identify the latest successful research and market-data updates.
Hedge Score 70 /100
BullishBullish
Confidence61%
Community Bullish0%
Followers2
Current Price₹8,300.001D +0.3%

Price History

DIVISLAB.NS chart

8,585.007,861.127,137.256,413.385,689.50 Aug 2025Oct 2025Dec 2025Feb 2026Apr 2026Jun 2026Aug 2026 2025-08-11 5,992.002026-02-10 6,175.502026-08-10 8,300.00

AI-Assisted Chart Analysis

Divi's Laboratories technical analysis

Calculated from verified chart history for the selected tenor; no news or fundamental assumptions are used.

Technical only
Trend

Constructive uptrend: the latest level is above the 50-period average and the 50-period average is above the 200-period average.

Momentum

RSI is 76, a extended reading. Above 70 can signal extension; below 30 can signal exhaustion.

Support scenario

The first technical watch zone is 7,188.50. A break below 6,521.00 invalidates the near-term support setup.

Resistance scenario

The first resistance/watch zone is 8,585.00. A confirmed break above 8,585.00 supports continuation.

Risk

Annualized realized volatility is +23.3%. Maximum lookback drawdown is -15.4%, from a high-water mark of 6,883.50 to 5,821.00.

Potential levels are conditional chart scenarios, not personalized advice or instructions to buy or sell.

How To Read This Stock Brief
Hedge Score

Higher means the current research setup is stronger across signal, confidence, catalysts, risk balance, and market context. Lower means the setup is weaker or less supported.

Confidence

Higher confidence means the evidence is more consistent and relevant. It does not mean the stock has that percentage chance of going up.

Signal

Bullish, Bearish, or Neutral is the current AI research stance. It is designed to help you ask better questions, not to replace your decision process.

Community Bullish

This shows how signed-in users are voting. It is useful sentiment context, not proof that the crowd is right.

Read the full Hedge Score and confidence methodology

What Changed Today

  • Divi's Laboratories has filed its official earnings call transcript in compliance with Regulation 30, providing the primary source for management's qualitative commentary on recent quarterly performance. This filing serves as the baseline for evaluating operational guidance, capacity utilization, and strategic outlook following the latest financial results. Market participants are simultaneously monitoring technical indicators, including RSI and MACD, which are currently reflecting the stock's recent price volatility.

Why It Matters

  • The earnings transcript is critical for reconciling management's forward-looking statements with the company's recent 21.26% monthly price appreciation, which contrasts with a 3.44% decline over the past week.
  • By analyzing the transcript, investors can better assess the sustainability of current margins and the strength of the contract manufacturing pipeline.
  • This qualitative data is essential for determining whether the recent valuation expansion is supported by fundamental operational improvements or if it is susceptible to a correction.

AI Opinion

  • Read: The current evidence-grounded AI read is bullish.
  • Evidence: The release of the earnings transcript is a standard procedural event that provides the necessary context to interpret the company's quantitative financial disclosures.
  • Uncertainty: Investors should prioritize management's commentary on API demand and capacity expansion, as these factors are the primary determinants of long-term earnings growth.
  • Watch: While technical indicators are being widely cited, they remain secondary to the fundamental operational guidance provided in the transcript.

Key Risks

  • Regulatory and compliance risks are inherent to the pharmaceutical sector; any management disclosure regarding facility inspections or delays in product approvals would negatively impact revenue growth projections. This would be confirmed by a lack of new product filings or adverse regulatory updates in subsequent disclosures.
  • Operational execution risk remains elevated if management commentary indicates unforeseen bottlenecks in scaling contract manufacturing capacity, which would directly compress operating margins. This risk would be confirmed by a sequential decline in EBITDA margins in the next quarterly report.

Upcoming Catalysts

  • The announcement of new material contracts or the expansion of existing partnerships would provide a clear signal of competitive strength and revenue visibility. This would be confirmed by management guidance indicating an increase in the order book or specific client wins.
  • Margin expansion driven by increased capacity utilization in the contract manufacturing segment would serve as a significant catalyst for valuation re-rating. This would be confirmed by sustained or improving EBITDA margins in future quarterly filings.

Upcoming Events

7:00 AM CSTDaily monitor scheduled

The automated scan is configured to refresh the stock brief each morning.

Market hoursPrice and news watch

The monitor checks price action, company news, filings, sector read-throughs, and major macro drivers.

Next catalystEvent watch

Upcoming earnings, product, policy, and industry events are tracked for thesis-changing updates.

Hedge Score Drivers

  • Verified evidence is currently bullish across the covered research lanes.
  • Evidence currently covers earnings and financial trends, sector and industry context, catalysts, risks, price and sentiment context.
  • Confidence is constrained by missing or incomplete evidence for balance-sheet strength, company operating KPIs, valuation.

Last Updated

Sources and verification

Each generated research claim remains linked to its supporting update. Primary evidence comes from filings, company materials, or regulators; secondary evidence provides additional context.

  • Divi's Laboratories RSI, Moving Averages, Technical Analysis MACD, MFI, Stochastic and Candlesticks of end of the day - Trendlyne.comSecondary sourceReportedNews · Published 2026-08-07Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divis Laboratories Ltd - 532488 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript - trendlyne.comSecondary sourceReportedNews · Published 2026-08-06Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Mutual Fund Jun 2026 share holdings and fund action in Divi's Laboratories - Trendlyne.comSecondary sourceReportedNews · Published 2026-07-31Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • The Hedge Book: Upcoming CatalystSecondary sourceReportedTrendlyne.com · Published 2026-08-07Open verification sourceSupports: Upcoming Catalysts
  • The Hedge Book: Upcoming CatalystSecondary sourceReportedTrendlyne.com · Published 2026-08-06Open verification sourceSupports: Upcoming Catalysts
  • The Hedge Book: Key RiskSecondary sourceReportedTrendlyne.com · Published 2026-08-07Open verification sourceSupports: Key Risks
  • The Hedge Book: Key RiskSecondary sourceReportedTrendlyne.com · Published 2026-08-06Open verification sourceSupports: Key Risks
  • The Hedge Book: AI OpinionSecondary sourceReportedTrendlyne.com · Published 2026-08-07Open verification sourceSupports: Company-Specific Research Updates
  • The Hedge Book: AI OpinionSecondary sourceReportedTrendlyne.com · Published 2026-08-06Open verification sourceSupports: Company-Specific Research Updates
  • The Hedge Book: Why It MattersSecondary sourceReportedTrendlyne.com · Published 2026-08-07Open verification sourceSupports: Why It Matters, AI Opinion
  • The Hedge Book: Why It MattersSecondary sourceReportedTrendlyne.com · Published 2026-08-06Open verification sourceSupports: Why It Matters, AI Opinion
  • The Hedge Book: What Changed TodaySecondary sourceReportedTrendlyne.com · Published 2026-08-07Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • The Hedge Book: What Changed TodaySecondary sourceReportedTrendlyne.com · Published 2026-08-06Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divi's Laboratories RSI, Moving Averages, Technical Analysis MACD, MFI, Stochastic and Candlesticks of end of the day - Trendlyne.comSecondary sourceReportedTrendlyne.com · Published 2026-07-17Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Accumulate Divis Laboratories; target of Rs 8600: Prabhudas Lilladher - Moneycontrol.comSecondary sourceReportedMoneycontrol.com · Published 2026-08-03Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • DIVISLAB Share Price Today: Divi's Laboratories NSE - TickertapeSecondary sourceReportedNews · Published 2026-07-30Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divis Laboratories Ltd Share Price Today - Zee BusinessSecondary sourceReportedNews · Published 2026-08-01Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divi 's Laboratories Limited - BSESecondary sourceOfficialNews · Published 2026-08-01Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divis Laboratories Ltd Share Price Today - Zee BusinessSecondary sourceReportedZee Business · Published 2026-08-02Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divis Laboratories Ltd - 532488 - Board Meeting Outcome for Outcome Of Board Meeting Held On August 01, 2026. - trendlyne.comSecondary sourceReportedNews · Published 2026-08-01Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divi’s Laboratories Q1 profit surges 66% to ₹902 crore, revenue rises 28% - CNBC TV18Secondary sourceReportedCNBC TV18 · Published 2026-08-01Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divi's Laboratories consolidated net profit rises 65.50% in the June 2026 quarter - Business StandardSecondary sourceReportedBusiness Standard · Published 2026-08-01Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divis Laboratories Ltd Share Price Today - zeebiz.comSecondary sourceReportedNews · Published 2026-08-02Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divi's Laboratories - DIVISLAB - stock price prediction, stock forecast, target price, analyst ratings from 30 analysts - Trendlyne.comSecondary sourceReportedNews · Published 2026-07-31Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divi’s Laboratories Q1 profit surges 66% to ₹902 crore, revenue rises 28% - cnbctv18.comSecondary sourceReportedNews · Published 2026-08-01Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
Market-data attributionYahoo Finance delayed market data · provider detailsMarket prices are supporting signals only and do not establish the research conclusion.

Community View

Sign in with Google to vote once per stock.

Bullish
Bearish
Neutral

Total votes: 0

Disclaimer

The Hedge Book provides AI-assisted educational market research. It is not a registered investment adviser, broker, dealer, or financial planner. Content may contain errors and should be independently verified. Do not treat this page as personalized advice to buy, sell, or hold any security.